<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="16955"><DrugName>99mTc-fanolesomab</DrugName><DrugNamesKey><Name id="42785672">99mTc-fanolesomab</Name><Name id="42751811">LeuTech</Name><Name id="42785668">NeutroSpec</Name><Name id="42751810">technetium (99mTc)  fanolesomab</Name><Name id="42829489">technetium-99m-fanolesomab</Name></DrugNamesKey><DrugSynonyms><Name><Value>technetium (99mTc)  fanolesomab</Value><Types><Type>PINN</Type></Types></Name><Name><Value>LeuTech</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>RB5-IgM</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NeutroSpec</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>anti-SSEA-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>99mTc RB5-IgM</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>99mTc anti-SSEA-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>99mTc-fanolesomab</Value><Types><Type>USAN</Type></Types></Name><Name><Value>99mTc-labeled anti-CD15 antibody</Value></Name><Name><Value>technetium-99m-fanolesomab</Value><Types><Type>USAN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24687">Palatin Technologies Inc</CompanyOriginator><CompaniesSecondary><Company id="1023217">Mallinckrodt Inc</Company><Company id="24687">Palatin Technologies Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16955" type="Drug"><TargetEntity id="253959" type="siDrug">Technetium Tc 99m Fanolesomab</TargetEntity></SourceEntity><SourceEntity id="1023217" type="Company"><TargetEntity id="4295904471" type="organizationId">Mallinckrodt LLC</TargetEntity></SourceEntity><SourceEntity id="24687" type="Company"><TargetEntity id="4295912241" type="organizationId">Palatin Technologies Inc</TargetEntity></SourceEntity><SourceEntity id="1135" type="ciIndication"><TargetEntity id="M86" type="ICD10"/><TargetEntity id="730" type="ICD9"/><TargetEntity id="10031252" type="MEDDRA"/><TargetEntity id="D010019" type="MeSH"/><TargetEntity id="-1522277951" type="omicsDisease"/><TargetEntity id="2362" type="siCondition"/></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="26" type="ciIndication"><TargetEntity id="10003011" type="MEDDRA"/><TargetEntity id="D001064" type="MeSH"/><TargetEntity id="-740516762" type="omicsDisease"/><TargetEntity id="2286" type="siCondition"/></SourceEntity><SourceEntity id="283" type="ciIndication"><TargetEntity id="10025082" type="MEDDRA"/><TargetEntity id="D008171" type="MeSH"/><TargetEntity id="-1582153652" type="omicsDisease"/><TargetEntity id="3451" type="siCondition"/></SourceEntity><SourceEntity id="443" type="ciIndication"><TargetEntity id="10020843" type="MEDDRA"/><TargetEntity id="D006979" type="MeSH"/><TargetEntity id="4034" type="siCondition"/></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity><SourceEntity id="5070" type="Action"><TargetEntity id="1584" type="Mechanism">Anti-CD15</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Appendicitis - US - Aug-2004</FirstLaunched></PhaseHighestDetailed><PhaseTerminated id="L">Launched</PhaseTerminated><IndicationsSecondary><Indication id="1135">Osteomyelitis</Indication><Indication id="189">Inflammatory bowel disease</Indication><Indication id="26">Appendicitis</Indication><Indication id="283">Lung disease</Indication><Indication id="443">Hyperthermia</Indication><Indication id="746">Infectious disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="4155">Imaging agent</Action><Action id="1617">Radiopharmaceutical</Action><Action id="4405">Radioimmunodiagnostic</Action><Action id="7213">Gastrointestinal diagnostic agent</Action><Action id="5070">CD15 antagonist</Action></ActionsSecondary><Technologies><Technology id="51">Monoclonal antibody</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="731">Imaging</Technology></Technologies><LastModificationDate>2019-01-19T05:55:42.000Z</LastModificationDate><ChangeDateLast>2019-01-21T00:00:00.000Z</ChangeDateLast><AddedDate>1998-01-19T12:29:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24687" linkType="Company"&gt;Palatin Technologies&lt;/ulink&gt; and &lt;ulink linkID="1023217" linkType="Company"&gt;Mallinckrodt&lt;/ulink&gt; have suspended sales, marketing, distribution and investigation  of 99mTc-fanolesomab (NeutroSpec, LeuTech, 99mTc-labeled anti-CD15 antibody), a radiolabelled imaging agent that had been developed and launched  for  the diagnosis of appendicitis, following reports of serious adverse events, including deaths, associated with use of the product [&lt;ulink linkID="275043" linkType="Reference"&gt;275043&lt;/ulink&gt;], [&lt;ulink linkID="641588" linkType="Reference"&gt;641588&lt;/ulink&gt;], [&lt;ulink linkID="641892" linkType="Reference"&gt;641892&lt;/ulink&gt;]. It was also under development for the diagnosis of other infections, including osteomyelitis [&lt;ulink linkID="313594" linkType="reference"&gt;313594&lt;/ulink&gt;]. It was launched in the US as NeutroSpec for appendicitis in August 2004 [&lt;ulink linkID="570083" linkType="Reference"&gt;570083&lt;/ulink&gt;]. Phase II trials in osteomyelitis were underway by November 1999 [&lt;ulink linkID="348390" linkType="reference"&gt;348390&lt;/ulink&gt;]; these studies,  plus phase II trials in post-surgical abscesses, fever of unknown origin, inflammatory bowel disease and pulmonary imaging, were ongoing in April 2003 [&lt;ulink linkID="484530" linkType="reference"&gt;484530&lt;/ulink&gt;];   by August 2005, these trials were still ongoing [&lt;ulink linkID="637627" linkType="Reference"&gt;637627&lt;/ulink&gt;].    By July 2005, Palatin planned to submit 99mTc-fanolesomab  for the diagnosis of appendicitis for regulatory approval in Europe, Canada and Latin America in 2005 [&lt;ulink linkID="611155" linkType="Reference"&gt;611155&lt;/ulink&gt;].  However, the drug was presumably discontinued.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By November 1999, a BLA had been submitted to the US FDA for appendicitis [&lt;ulink linkID="348390" linkType="reference"&gt;348390&lt;/ulink&gt;], [&lt;ulink linkID="313594" linkType="reference"&gt;313594&lt;/ulink&gt;]; this was accepted for full review in February 2000, following the initial 60-day review [&lt;ulink linkID="354252" linkType="reference"&gt;354252&lt;/ulink&gt;]. In July 2000, an advisory panel meeting voted unanimously to determine 99mTc-fanolesomab as safe and effective [&lt;ulink linkID="373921" linkType="reference"&gt;373921&lt;/ulink&gt;]; however, in September 2000, the company received a Complete Response letter in which the FDA requested additional manufacturing and process validation data prior to approval [&lt;ulink linkID="384014" linkType="reference"&gt;384014&lt;/ulink&gt;]. Palatin started the BLA amendment filings for 99mTc-fanolesomab in the first half of 2003, and the majority of the data requested was submitted in a BLA amendment filed in September 2003; the company anticipated filing the remaining data as a supplement to the BLA amendment in the fourth quarter of 2003 [&lt;ulink linkID="506950" linkType="reference"&gt;506950&lt;/ulink&gt;]. In July 2004, the FDA approved 99mTc-fanolesomab for diagnosis of appendicitis. The compound was to be marketed and distributed by Mallinckrodt [&lt;ulink linkID="547606" linkType="reference"&gt;547606&lt;/ulink&gt;], [&lt;ulink linkID="547577" linkType="reference"&gt;547577&lt;/ulink&gt;]. It was launched in August 2004 [&lt;ulink linkID="570083" linkType="Reference"&gt;570083&lt;/ulink&gt;]. In December 2005, Palatin and Mallinckrodt informed healthcare professionals of a potential health risk of 99mTc-fanolesomab. Several patients with severe underlying cardiopulmonary comorbidities had experienced life-threatening or fatal reactions after administation for off-label indications [&lt;ulink linkID="638509" linkType="Reference"&gt;638509&lt;/ulink&gt;]. Later in December 2005, sales, marketing, distribution and investigation of 99mTc-fanolesomab were suspended following reports of serious adverse events, including deaths, associated with use of the product. The companies were reviewing the reports and were to meet with the FDA in early 2006 to discuss their findings and any additional safety measures that could allow the product to return to the market [&lt;ulink linkID="641588" linkType="Reference"&gt;641588&lt;/ulink&gt;], [&lt;ulink linkID="641892" linkType="Reference"&gt;641892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2005, Palatin planned to submit 99mTc-fanolesomab  for the diagnosis of appendicitis for regulatory approval in Europe, Canada and Latin America in 2005 [&lt;ulink linkID="611155" linkType="Reference"&gt;611155&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Appendicitis&lt;/subtitle&gt;In June 2000, results of a phase III trial were presented at the 47th Society of Nuclear Medicine meeting in St Louis, MO. The open-label trial included 200 patients who presented to emergency departments with equivocal appendicitis at ten sites across the US [&lt;ulink linkID="369709" linkType="reference"&gt;369709&lt;/ulink&gt;]. 99mTc-fanolesomab demonstrated a 91% sensitivity and 86% specificity; 99mTc-fanolesomab also demonstrated a negative predictive value of 96%. Diagnostic efficacy was unchanged in a subgroup of 48 pediatric patients, and no serious or severe adverse affects were reported. Finally, diagnostic images with 99mTc-fanolesomab were achieved within 8 min post-injection for 50% of patients and within 47 min for 90% of patients [&lt;ulink linkID="370190" linkType="reference"&gt;370190&lt;/ulink&gt;]. The FDA evaluated the safety profile of 99mTc-fanolesomab based on data from a total of 439 subjects, which shows that the most common adverse reaction was vasodilation or flushing (2.5% of all subjects) [&lt;ulink linkID="376524" linkType="reference"&gt;376524&lt;/ulink&gt;]. However, the FDA committee recommended several post-approval trials of 99mTc-fanolesomab to further clarify its role, including a study in neutropenic patients, particularly in children under 5 years. As of July 2000, a trial was underway to confirm the pediatric dosing recommendations [&lt;ulink linkID="376524" linkType="reference"&gt;376524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II and III trial results were presented to the 46th Annual Meeting of the Society of Nuclear Medicine in Los Angeles in June 1999. These demonstrated that 99mTc-fanolesomab is highly sensitive for the detection and diagnosis of equivocal appendicitis [&lt;ulink linkID="327911" linkType="reference"&gt;327911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, clinical results from a trial investigating 99mTc-fanolesomab for diagnosing equivocal appendicitis were presented at Digestive Disease Week in Orlando, FL. A total of 49 patients with RLQ pain and equivocal history, physical exam or lab tests were evaluated by surgeons and deemed to have an equivocal presentation. The surgeon specified treatment plan prior to WBC scan and the prescan plan was compared with actual management after receiving scan results. 99mTc-fanolesomab changed patient management and reduced the risks of managing equivocal appendicitis by eliminating admission and observation, avoiding discharging two patients with appendicitis and operating on one without it [&lt;ulink linkID="327020" linkType="reference"&gt;327020&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company initiated a phase III trial in September 1998 for the diagnosis of appendicitis [&lt;ulink linkID="302827" linkType="reference"&gt;302827&lt;/ulink&gt;]. In March 1999, the company completed patient enrollment at ten major US sites [&lt;ulink linkID="318598" linkType="reference"&gt;318598&lt;/ulink&gt;]. The trial was completed in April 1999, with results showing that the agent was safe, could detect appendicitis in 91% of positive subjects and could predict the absence of appendicitis in 96% of negative scans [&lt;ulink linkID="322706" linkType="reference"&gt;322706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II trial for the diagnosis of appendicitis was successfully concluded in June 1998. A meeting with the FDA was held in July 1998, to review the phase I and II trial data for 99mTc-fanolesomab [&lt;ulink linkID="290483" linkType="reference"&gt;290483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteomyelitis&lt;/subtitle&gt;In June 2004, clinical data comparing the use of 99mTc-fanolesomab with the use of 111In-labeled leukocytes and three-phase bone imaging to diagnose osteomyelitis were presented at the Society for Nuclear Medicine's 51st annual meeting in Philadelphia, PA. In a single-center, retrospective, blinded review of 28 patients diagnosed with osteomyelitis (confirmed by histopathology or microbiology), diagnosis with 99mTc-fanolesomab (images taken 1 h post-administration), 111In-leukocyte (images taken 24 h post-administration) and three-phase bone imaging was correct in 19 (68%), 20 (71%) and 17 (61%) patients, respectively. Combining either technique with three-phase bone imaging gave the same results. Osteomyelitis was identified in 14 patients; 12 (86%), 9 (64%) and 12 (86%) of these patients were correctly diagnosed by 99mTc-fanolesomab, 111-In-leukocytes and three-phase bone imaging, respectively [&lt;ulink linkID="546288" linkType="reference"&gt;546288&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, Palatin published phase II results evaluating the efficacy of 99mTc-fanolesomab in 25 diabetic patients with suspected pedal osteomyelitis. The accuracy of 99mTc-fanolesomab and 111In-labeled white blood cells (111In WBC) were equivalent for both patients with and without pedal osteomyelitis; 10 patients had a positive diagnosis of pedal osteomyelitis and 15 patients were confirmed to have a negative diagnosis [&lt;ulink linkID="487070" linkType="reference"&gt;487070&lt;/ulink&gt;]. These results were also published in January 2003 [&lt;ulink linkID="500277" linkType="reference"&gt;500277&lt;/ulink&gt;], [&lt;ulink linkID="506950" linkType="reference"&gt;506950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, Palatin announced positive interim results from its phase II trial of 99mTc-fanolesomab in diabetic patients with pedal ulcers and possible osteomyelitis at the Society of Nuclear Medicine meeting in Toronto, Canada. The safety and utility of 99mTc-fanolesomab was assessed, along with making a comparison between 99mTc-fanolesomab and indium-oxine labeled white blood cells and 3-phase bone scan, the current standards of care. In all cases, 99mTc-fanolesomab produced a diagnostic image in less than 1 h compared to the 24 h required for the indium-oxine method [&lt;ulink linkID="413507" linkType="reference"&gt;413507&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II trials for the diagnosis of osteomyelitis began in February 1999 [&lt;ulink linkID="313594" linkType="reference"&gt;313594&lt;/ulink&gt;], and by July 2000, two phase II trials for osteomyelitis were underway [&lt;ulink linkID="376524" linkType="reference"&gt;376524&lt;/ulink&gt;], [&lt;ulink linkID="501563" linkType="reference"&gt;501563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In June 2004, clinical data on 99mTc-fanolesomab were presented at the Society of Nuclear Medicine's 51st annual meeting in Philadelphia, PA. In a study of 24 patients with suspected occult infection, 99mTc-fanolesomab, using scintigraphic analysis up to 2 hour post-iv injection, was used to correctly diagnose 23 patients; 3 of 4 genuine infections were diagnosed and all 20 negative diagnoses were correct (the misdiagnosed patient was correctly diagnosed on a subsequent 24 h post-injection scan). In comparison, use of 111In-WBCs enabled correct diagnosis of 20 out of 22 patients evaluated; all 4 genuine infections were diagnosed and 16 of 18 negative diagnoses were identified [&lt;ulink linkID="546287" linkType="reference"&gt;546287&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of July 2000, a phase II trial was underway to examine 99mTc-fanolesomab for use in post-operative abscesses, each enrolling 25 patients, were underway. The company was also planning a fourth trial in inflammatory bowel disease [&lt;ulink linkID="376524" linkType="reference"&gt;376524&lt;/ulink&gt;], [&lt;ulink linkID="501563" linkType="reference"&gt;501563&lt;/ulink&gt;], which had begun by April 2003 [&lt;ulink linkID="484530" linkType="reference"&gt;484530&lt;/ulink&gt;]. Also by this time phase II trials had begun for hyperthermia and pulmonary disease [&lt;ulink linkID="484530" linkType="reference"&gt;484530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of a phase I trial, completed in January 1998, showed that there were no adverse effects in ten healthy volunteers [&lt;ulink linkID="275043" linkType="reference"&gt;275043&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2004, Palatin agreed with the FDA to change the trade name from LeuTech to NeutroSpec to avoid confusion and reduce the chance of a medication error [&lt;ulink linkID="540708" linkType="reference"&gt;540708&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 1998, Palatin was seeking corporate partners to assist in the development of the product for the European and Asian markets and a US sales and marketing partner [&lt;ulink linkID="304195" linkType="reference"&gt;304195&lt;/ulink&gt;]. In August 1999, Palatin and Mallinckrodt entered an agreement giving Mallinckrodt an exclusive worldwide license (excluding Europe) for the sales, marketing and distribution of LeuTech [&lt;ulink linkID="336916" linkType="reference"&gt;336916&lt;/ulink&gt;]. This agreement was amended in May 2002, to cover half of Palatin's estimated expenses associated with completing the FDA review process [&lt;ulink linkID="451197" linkType="reference"&gt;451197&lt;/ulink&gt;]. In August 2004, Palatin received a $2 million milestone payment from Mallinckrodt following the FDA's approval of 99mTc-fanolesomab [&lt;ulink linkID="553272" linkType="Reference"&gt;553272&lt;/ulink&gt;], [&lt;ulink linkID="558901" linkType="Reference"&gt;558901&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Charito Love &amp;amp; Christopher J Palestro, Division of Nuclear Medicine, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040, USA &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 22 July 2003&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 06 October 2003&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Presently, radionuclide imaging for infection with the use of human leukocytes involves withdrawal of blood from a patient, in vitro labeling of autologous leukocytes with either 99mTc-HMPAO or [111]In-oxine, and re-injection of labeled cells into the patient. The process is time-consuming, laborious, inconvenient and associated with personnel risk of exposure to blood elements. In addition, when using [111]In-oxine for labeling, other problems exist, such as limited availability of the agent, the need for next-day imaging and poor spatial resolution of images. A satisfactory in vivo method of labeling leukocytes with the widely available radionuclide, 99mTc-pertechnetate would overcome many of these problems. One method of labeling leukocytes in vivo is to complex the radionuclide with an agent that reacts specifically with a surface antigen on human leukocytes [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;]. Among the agents that have been investigated is a murine monoclonal IgM class antibody, &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; (LeuTech). This agent, which has been successfully labeled with 99mTc-pertechnetate, exhibits affinity for the glycoprotein antigen CD15, expressed on human leukocytes [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;]. The labeled antibody is injected directly into a patient, thus eliminating the problems associated with in vitro labeling of leukocytes [&lt;ulink linkType="reference" linkID="500214"&gt;500214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Originally raised against stage-specific embryonic antigen (SSEA)-1 in mice immunized with murine embryonal carcinoma F9 cells, the monoclonal IgM antibody, anti-SSEA-1 has a molecular weight of ~ 900 kDa. Anti-SSEA-1 was chosen for clinical development because of its availability in purified form, high specificity and high degree of interaction with human neutrophils in whole blood. Graduated activity dilution and scatchard plots were used to demonstrate that it exhibits a high affinity (association constant Kd = 10(-11) M) for the carbohydrate moiety 3-fucosyl-N-acetyl lactosamine contained in the CD15 antigen, expressed on human neutrophils, eosinophils and lymphocytes [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Antibody production was carried out in tissue culture using the hybridoma cell line RB-5. Sulfhydryl groups to facilitate 99mTc binding were generated by reduction under controlled conditions; stabilizing and reducing agents were added before the antibody was placed in glass vials [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The anti-CD15 antibody is supplied as a lyophilized sterile unit dose kit containing 250 microg of antibody that can be reconstituted and labeled instantly. The kit should be stored at 2 to 8degreesC [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;]. At the time of labeling, 40 mCi of 99mTc-pertechnetate in a 0.20- to 0.35-ml solution is added to the vial and incubated for 30 min at 37degreesC. To stabilize the radiolabeled antibody and to dilute the solution, 500 mg/ml of ascorbic acid is added to the vial to bring the final volume to 1.0 ml. Prior to patient administration, the preparation should be tested for radiochemical purity through instant thin layer chromatography (ITLC). The product should be used only if the percentage of unbound 99mTc is &amp;lt;/= 10% and used within 6 h after reconstitution [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;]. The recommended dose of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; to be administered is 75 to 125 microg of antibody bound to 370 to 740 MBq (10 to 20 mCi) 99mTc [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical Development&lt;/subtitle&gt;The affinity of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; for the CD15 receptor on neutrophils is 1.6 x 10(-11) M [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;]. The concentration of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; bound at 50% of maximum binding is 0.44 to 1.05 x 10(-8) M [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;] and the leukocyte labeling efficiency is 80 +/- 4%. Binding is upregulated with neutrophil activation; the antibody binds to neutrophils in greater proportion than to any other cell type and this binding increases proportionately with increasing numbers of neutrophils in circulation [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;]. Less than 1% of activity is bound to lymphocytes and platelets. An average of 3.9 +/- 0.9% of the activity is associated with erythrocytes. The activity bound to the recovered granulocyte fraction is 40.7 +/- 8.2%. Spectrometry and graduated activity dilution methods were used to determine that each neutrophil has approximately 5.1 x 10(5) CD15 receptors on its surface [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;]. At 10% receptor occupancy by the antibody, the phagocytic and adherence functions of the neutrophils are diminished by 70 and 80%, respectively. At 4 to 5% receptor occupancy, no effect on neutrophil function is observed. The chemotactic function of neutrophils is not affected by the degree of receptor occupancy. A minimum of 1 mg of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; is needed to saturate 4% of the surface receptors on neutrophils. The total amount of antibody supplied in the kit is ~ 250 microg; the usual dose injected contains 75 to 125 microg of antibody [&lt;ulink linkType="reference" linkID="500216"&gt;500216&lt;/ulink&gt;], which is well below the amount needed to produce pharmacological effects. &lt;/para&gt;&lt;para&gt;The antibody is thought to bind to circulating neutrophils, which eventually migrate to the focus of infection, in addition to neutrophils, and even neutrophilic debris containing receptors, already sequestered in the area of infection. This may explain the increasing intensity of activity in the area of infection following injection of the tracer [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500214"&gt;500214&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and Pharmacokinetics&lt;/subtitle&gt;Following intravenous injection, the agent is rapidly distributed with a mean distribution half-life of 0.3 h [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;]. The mean linear elimination half-life for blood clearance is 8 h (monoexponential half-life = 5.7 h) [&lt;ulink linkType="reference" linkID="500217"&gt;500217&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;]. Bone marrow activity peaks shortly after administration, with a longer elimination time compared with background tissues. The organ in which the most radioactivity accumulates is the liver, followed by the spleen and bladder. Peak liver activity consists of 45 to 50% of the injected dose, decreasing to 25 to 40% of the injected dose by 24 h. Spleen activity peaks at 5 to 12% of the injected dose and drops by half within 24 h. Several tissues known to contain surface receptors identical to SSEA-1/CD15, such as salivary glands, brain, breasts, eyes and ovaries, are not visualized. A low level of activity is seen in the testes. No activity crosses the blood-brain barrier. Activity is normally present in the colon after 24 h. There are minimal differences in the absorbed radiation doses between male and female patients. The dose-limiting organ is the spleen, which receives an estimated 0.064 mGy/MBq (0.24 rads/mCi), an amount that is considerably lower than the estimated 90 mGy (9 rads) for the typical dose of 18.5 MBq (0.5 mCi) 111In-labeled leukocytes [&lt;ulink linkType="reference" linkID="500218"&gt;500218&lt;/ulink&gt;]. There is a rapid accumulation of radioactivity in target sites as early as 10 min post-injection [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Excretion is primarily through the kidneys. Renal excretion fractions vary from 31 to 49% over 26 to 31 h (mean = 39.5 +/- 6.5%). The sum of radioactivity excreted in the urine and the remaining radioactivity in the whole body varied by &amp;lt;/= 3% of the injected dose during the first 8 h and by &amp;lt;/= 5% during the first 24 h [&lt;ulink linkType="reference" linkID="500218"&gt;500218&lt;/ulink&gt;]. Radioactivity excreted in the urine is not antibody bound [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As neutrophils of other species do not express the CD15 receptor, &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; does not bind to neutrophils of other species [&lt;ulink linkType="reference" linkID="500213"&gt;500213&lt;/ulink&gt;]; consequently, animals commonly employed in the laboratory were not used to define the activity of this antibody. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;There are no published data on the toxicity profile of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt;. Independent industry-sponsored cytotoxicity studies, however, have been performed. Cytotoxicity was measured for isolated human WBCs in autologous plasma. In the presence of complement factors, the minimum concentration of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; necessary to cause lysis in 48% of neutrophils was 1 microg/ml. At concentrations of 2 to 5 microg/ml, all the cells were lysed. Following exposure to complement factors, lysis occurred within 5 min and was completed by 30 min. In whole blood from normal donors, the cytotoxic dose was 2 microg/ml or higher. No cytotoxic effects were seen at 0.2 microg/ml. The dose of 100 microg/patient during the initial clinical trials provided an approximately 0.02 microg/ml blood antibody dose, 10-fold less than the minimum dose for which cytotoxicity could be demonstrated [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Intravenous cytotoxicity studies were performed in mice and rabbits using bioreactor-produced anti-CD15 antibody prepared according to the formulation intended for commercial distribution. To simulate the clinical setting, &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; kits were reconstituted with decayed 99mTc. Graduated doses from 10- to 200-fold the maximum anticipated human dose were injected. Following an observation phase, animals were sacrificed and histopathologic examinations were performed. Antibody treatment up to 200-fold the maximum anticipated human dose had no adverse effects on survival, clinical conditions, hematologic or serum biological parameters, or on gross or microscopic histology. The No Observable Effect Level (NOEL) dose in these studies was &amp;gt; 500 mg/kg [&lt;ulink linkType="reference" linkID="506976"&gt;506976&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I study with ten healthy volunteers was conducted to evaluate blood clearance, cell binding, urinary excretion, biodistribution, human radiation dosimetry and safety of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="500218"&gt;500218&lt;/ulink&gt;]. Each volunteer received a single 370 to 555 MBq (10 to 15 mCi) dose of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; containing 75 to 125 microg of the antibody. All subjects underwent imaging following injection at specified time points up to 30 h. Activity in the venous blood was serially determined up to 24 h post-injection and activity in urine collected within 24 h was also determined. Clinical chemistry and hematological testing prior to, and serially up to, 24 h after injection were performed. Subjective symptoms and vital signs were also monitored. There was rapid distribution of the radioactivity after intravenous injection with a mean distribution half-life of 0.3 h. An average of 19% of the injected dose was bound to neutrophils at 30 min, increasing to an average of 25% at 60 min. The only significant observation was a decrease in peripheral WBC count within 3 to 60 min after injection, with increased levels above baseline at 4 h and a return to baseline levels by 18 to 24 h post-injection. There were no associated changes in vital signs or subjective well being of the subjects. The initial mean urinary excretion half-life was 2.39 h and the terminal phase was 171.3 h. Given the 6-h half-life of 99mTc, the impact on the residency time of the radioactivity within the body is negligible [&lt;ulink linkType="reference" linkID="500218"&gt;500218&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;There is a transient decrease in the number of circulating white blood cells (WBCs) from a mean (+/- SD) of 5.7 +/- 2.1 to 3.2 +/- 1.3 x 10(3) microl blood in healthy volunteers within the first 20 min after injection of the antibody and a decrease in the relative number of granulocytes from 57.2 +/- 10.5 to 35.3 +/- 17.7% of total circulating WBCs. The effects on the other blood cells are qualitatively similar but less pronounced. As the total number of WBCs drops, the percentage of lymphocytes increases. There is no evidence of clustering, cell fragmentation or morphological cell changes during this transient phenomenon; in addition, there are no associated clinical complaints. Recovery is rapid, with an average time of 20 min, reflecting rapid and constant release of granulocytes from the bone marrow. On imaging, activity is initially distributed in the cardiovascular system. Bone marrow spaces in the axial and appendicular skeleton are well visualized. Splenic and hepatic activity peak at 25 to 35 min following injection, coinciding with the nadir of circulating granulocytes and percentage whole-blood activity bound to WBCs. It is believed that as the reticuloendothelial system has a propensity to retard transit of coated blood cells, hepatosplenic sequestration may explain, in part, the transient decrease in the number of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt;-labeled blood cells and recovery with time. In contrast to leukocytes that are labeled in vitro, there is no increased retention of activity in the lungs following injection of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="500217"&gt;500217&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A study to assess formation of human antimouse antibody (HAMA) and safety of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; administration was undertaken in 30 healthy subjects. Each subject received 125 microg of antibody labeled with 99mTc that was decayed for at least 48 h. Blood samples were obtained before and at 3 to 4 weeks and 3 to 4 months after injection of the antibody. There was no statistically significant elevation of HAMA titer following injection. No adverse reactions of any kind or changes in vitals signs were observed. The agent presented no significant risk for formation of HAMA antibody, and could safely be used for infection imaging [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II study, designed to assess the efficacy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; for diagnosing appendicitis in patients with equivocal signs and symptoms and to determine the potential impact of the study in patient management, was undertaken with 56 patients (25 male and 31 female, aged nine to 77 years) suspected of appendicitis. Adult patients received a single dose containing 370 to 740 MBq (10 to 20 mCi) of radioactivity. In patients aged under 18 years, the dose was adjusted to 7.8 MBq (0.21 mCi)/kg body weight up to a maximal dose of 740 MBq (20 mCi). Three blinded readers who had no knowledge of the final diagnoses evaluated all images. Sensitivity, specificity and accuracy ranged from 82 to 93%, 54 to 82%, and 73 to 82%, respectively. The positive predictive value ranged from 66.7 to 82.1% and the negative predictive value from 78.3 to 88.2%. There was marked improvement in the number of patients for whom the correct management decision had been made, from 21.4% pre-scan to 78.6% post-scan. Correct management determination avoided two laparotomies, 29 unnecessary admissions, and two patients with appendicitis being sent home. A few patients observed momentary flushing that resolved spontaneously and required no treatment. There were cases of variable blood pressure and pulse rate (both increases and decreases) that resolved spontaneously without treatment and were deemed to be unrelated to the antibody administration [&lt;ulink linkType="reference" linkID="327020"&gt;327020&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="399498"&gt;399498&lt;/ulink&gt;]. This phase II study demonstrated that &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; is safe and shows potential for efficacy in the diagnosis of appendicitis in patients presenting with equivocal signs and symptoms. &lt;/para&gt;&lt;para&gt;A trial of 17 patients with infectious foci was carried out to compare the activity of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; with Tc-HMPAO-labeled WBCs [&lt;ulink linkType="reference" linkID="500214"&gt;500214&lt;/ulink&gt;]. Imaging and blood analyses were carried out at various time points post-injection. Of a total of 23 lesions, all were detected by &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; imaging, whereas only 21 lesions were detected by Tc-HMPAO-labeled WBCs [&lt;ulink linkType="reference" linkID="500214"&gt;500214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Another phase II study to assess the accuracy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; in diagnosing osteomyelitis and compare it with [111]In-WBC imaging was undertaken in 24 patients (ten males and 14 females, aged 48 to 91 years) suspected of infected joint replacement (n = 12), diabetic pedal osteomyelitis (n = 8) or long bone osteomyelitis (n = 4). At different time points, sensitivity, specificity and accuracy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; ranged from 73 to 91%, 69 to 77% and 75 to 79%, respectively. For 111In-WBC, sensitivity, specificity and accuracy were 91, 62 and 75%, respectively. This phase II study demonstrated that &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; was safe, and shows potential efficacy for diagnosis of osteomyelitis [&lt;ulink linkType="reference" linkID="500219"&gt;500219&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;An additional phase II study designed to assess the accuracy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; for diagnosing pedal osteomyelitis in diabetics (n = 25) was undertaken. &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; was compared with 111In-labeled leukocyte and 3-phase bone imaging. The sensitivity, specificity and accuracy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; were 90, 67 and 76%, respectively. Results demonstrated that &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; was slightly but not significantly more sensitive than [111]In-labeled leukocyte imaging and as sensitive as 3-phase bone imaging. Its specificity, identical to that of [111]In-labeled leukocyte scintigraphy, was significantly (p = 0.004) higher than that of the 3-phase bone scan [&lt;ulink linkType="reference" linkID="413507"&gt;413507&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="487070"&gt;487070&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500277"&gt;500277&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;A multicenter trial was conducted to assess the efficacy of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; for diagnosing acute appendicitis in patients with an equivocal presentation, to evaluate its safety and to assess the potential impact of this agent on the intended clinical management of such patients. A total of 200 patients (121 females and 79 males, aged five to 86 years) were enrolled. Management plans were formulated both before and after &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; imaging. Of these patients, 59 had histopathologically confirmed acute appendicitis. Sensitivity, specificity and accuracy were 91, 86 and 87%, respectively. The positive and negative predictive values were 73 and 96%, respectively. Following administration of &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt;, images were positive at 8 min in 50% and at 47 min in 90% of patients with acute appendicitis, making time to diagnosis short. The high negative predictive value indicates that &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; is a useful screening tool for suspected acute appendicitis. In this study, &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; scintigraphy was determined to be safe, convenient, rapid and sensitive for the detection of acute appendicitis in adult and pediatric patients with equivocal presentation. There was a significant improvement (p &amp;lt;/= 0.001) in the appropriate management decision being made after the scan [&lt;ulink linkType="reference" linkID="322706"&gt;322706&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="370190"&gt;370190&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="474714"&gt;474714&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="501563"&gt;501563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;Among 439 individuals who were injected with &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt;, only 30 individuals (6.8%) reported adverse events. In only half of these cases were the events reported as possibly or probably related to the antibody. The most frequently reported adverse event was vasodilatation experienced as flushing (incidence 2.5%). Dyspnea was reported in four subjects (incidence 0.9%); two were considered drug-related. Paresthesia was reported by three patients (incidence 0.7%) [&lt;ulink linkType="reference" linkID="501563"&gt;501563&lt;/ulink&gt;]. Other reported adverse events by more than one patient include headache, pain, syncope, dizziness and pharyngitis. No serious adverse event or death occurred,  and no individual discontinued the study due to an adverse event [&lt;ulink linkType="reference" linkID="376524"&gt;376524&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="399498"&gt;399498&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="474714"&gt;474714&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500217"&gt;500217&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500218"&gt;500218&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500219"&gt;500219&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500277"&gt;500277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Available data indicate that &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; is useful in patients with equivocal presentation of acute appendicitis and may serve as a screening test for acute appendicitis. Due to the short time to diagnosis, &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; can potentially be used in the emergency room in patients with right lower quadrant pain who are suspected of acute appendicitis. This agent can also potentially be utilized as rapid diagnostic imaging agent for osteomyelitis, especially in diabetic patients with foot ulcers suspected to be osteomyelitis. &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; imaging provides an answer in a few hours rather than 24 h, as in the case with [111]In-labeled leukocyte imaging. The agent is safe with no serious adverse side effects associated with its administration.&lt;/para&gt;&lt;para&gt;Another neutrophil-specific monoclonal antibody, &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; (LeukoScan, &lt;ulink linkType="Company" linkID="17204"&gt;Immunomedics Inc&lt;/ulink&gt;), has been evaluated and was launched in 1997 in Europe. In addition, &lt;ulink linkType="Company" linkID="14143"&gt;CIS Bio International&lt;/ulink&gt; has developed a kit to radiolabel the neutrophil-specific anti-NCA-95 antibody BW-250/183 with 99mTc [&lt;ulink linkType="reference" linkID="506973"&gt;506973&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The affinity constant of &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; for neutrophils is approximately 0.5 x 10(-8) M [&lt;ulink linkType="reference" linkID="195097"&gt;195097&lt;/ulink&gt;], this compares with an affinity of 1.6 x 10(-11) M for &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="474716"&gt;474716&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500212"&gt;500212&lt;/ulink&gt;]. Approximately 3 to 6% of the injected activity of &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; is associated with circulating neutrophils and at 24 h following injection, approximately 35% of the activity remaining in the body is in the bone marrow [&lt;ulink linkType="reference" linkID="195097"&gt;195097&lt;/ulink&gt;]. This agent has been observed on delayed imaging up to 17 to 19 h post-injection in the major vessels and heart. There is also considerable activity in the hematopoetically active marrow of the axial skeleton, potentially precluding diagnosis of small foci of infection in these sites [&lt;ulink linkType="reference" linkID="507005"&gt;507005&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="507007"&gt;507007&lt;/ulink&gt;]. Clinical results with &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; have been variable. The sensitivity, specificity and accuracy of &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; range from 76 to 100, 67 to 100 and 78 to 90%, respectively [&lt;ulink linkType="reference" linkID="507007"&gt;507007&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="507021"&gt;507021&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="507029"&gt;507029&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="507030"&gt;507030&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="507031"&gt;507031&lt;/ulink&gt;], this compares with sensitivity, specificity and accuracy ranges of 73 to 100, 54 to 86 and 73 to 93% for &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="474714"&gt;474714&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="327020"&gt;327020&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500219"&gt;500219&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="500277"&gt;500277&lt;/ulink&gt;]. As with &lt;ulink linkType="Drug" linkID="16955"&gt;99mTc-fanolesomab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="9867"&gt;sulesomab&lt;/ulink&gt; does not produce a HAMA response.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="26">Appendicitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1135">Osteomyelitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="746">Infectious disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="443">Hyperthermia</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1135">Osteomyelitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="26">Appendicitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="283">Lung disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="746">Infectious disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="283">Lung disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="443">Hyperthermia</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="443">Hyperthermia</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="443">Hyperthermia</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2005-12-19T00:00:00.000Z</StatusDate><Source id="641588" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2004-07-02T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="348390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2004-07-02T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="443">Hyperthermia</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate>1999-02-05T00:00:00.000Z</StatusDate><Source id="313594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023217">Mallinckrodt Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="570083" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="443">Hyperthermia</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate>1999-02-05T00:00:00.000Z</StatusDate><Source id="313594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="484530" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="570083" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="348390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>1998-11-09T00:00:00.000Z</StatusDate><Source id="304195" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24687">Palatin Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="26">Appendicitis</Indication><StatusDate>1998-01-19T00:00:00.000Z</StatusDate><Source id="275043" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1085756">Mallinckrodt plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24687">Palatin Technologies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="122534" title="Mallinckrodt to market Palatin Technologies' Leutech worldwide excluding Europe "/></Deals><PatentFamilies><PatentFamily id="14979" number="US-04917878" title="Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals."/><PatentFamily id="15215" number="WO-09101754" title="Direct radiolabeling of antibodies and other proteins with technetium or rhenium."/><PatentFamily id="318122" number="WO-09637239" title="Peptide Radiopharmaceutical Applications"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rhomed Inc" id="19233"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thomas Jefferson University" id="20685"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Palatin Technologies Inc" id="24687"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>